| dc.contributor.author | Molari, Wilson Santos | |
| dc.contributor.author | Jmel, Mohamed Amine | |
| dc.contributor.author | Assis, Josiane Betim | |
| dc.contributor.author | Frazão-Silva, Alan | |
| dc.contributor.author | Bernardi, Julia Moura | |
| dc.contributor.author | Huamanrayme, Gretta | |
| dc.contributor.author | Medina, José María | |
| dc.contributor.author | Esteves, Eliane | |
| dc.contributor.author | Antão, Solange Cristina | |
| dc.contributor.author | Costa, Gabriel Cerqueira Alves | |
| dc.contributor.author | Tanaka, Aparecida Sadae | |
| dc.contributor.author | Fogaca, Andréa Cristina | |
| dc.contributor.author | Franta, Zdenek | |
| dc.contributor.author | Tirloni, Lucas | |
| dc.contributor.author | Kotsyfakis, Michalis | |
| dc.contributor.author | Sá-Nunes, Anderson | |
| dc.date.accessioned | 2025-11-18T10:24:39Z | |
| dc.date.available | 2025-11-18T10:24:39Z | |
| dc.date.issued | 2025-07-17 | |
| dc.identifier.citation | Amblyostatin-1, the first salivary cystatin with host immunomodulatory and anti-inflammatory properties from the Neotropical tick Amblyomma sculptum, vector of Brazilian spotted fever | cs_CZ |
| dc.identifier.issn | 1664-3224 | |
| dc.identifier.uri | https://dspace.jcu.cz/handle/20.500.14390/47548 | |
| dc.description.abstract | Introduction: The Neotropical tick Amblyomma sculptum is the primary vector
of Rickettsia rickettsii, the causative agent of Brazilian spotted fever, a disease
associated with high fatality rates. Tick saliva, a complex mixture of bioactive
molecules essential for successful blood feeding, facilitates pathogen
transmission and modulates host immune responses. A comprehensive
evaluation of the salivary gland transcriptome database reveals that protease
inhibitors are abundantly expressed molecules in tick saliva during feeding. Thus,
this study aims to describe and characterize the most expressed member of the
cystatin family identified in Amblyomma sculptum salivary transcriptome, named
Amblyostatin-1.
Methods: Bioinformatic tools were employed for in silico analysis of the
Amblyostatin-1 sequence and structure. A recombinant version of
Amblyostatin-1 was expressed in an Escherichia coli system, evaluated against
a panel of cysteine proteases in biochemical assays, and used to generate antibodies in immunized mice. The biological activities of Amblyostatin-1 were
assessed by its effects on dendritic cell maturation in vitro and in a carrageenaninduced
inflammation model in vivo.
Results: Based on its sequence and predicted three-dimensional structure,
Amblyostatin-1 is classified as an I25B cystatin, and its recombinant form
selectively inhibits cathepsins L, C, and S at different rates, with a low
nanomolar Ki value of 0.697 ± 0.22 nM against cathepsin L. Regarding its
biological activities, recombinant Amblyostatin-1 partially affects LPS-induced
dendritic cell maturation by downmodulating the costimulatory molecules CD80
and CD86 at higher micromolar concentrations (3 μM) while promoting IL-10
production at nanomolar concentrations (100 nM). The apparent lack of
Amblyostatin-1-specific antibody responses in immunized mice suggests an
impairment of antigen processing and presentation in vivo. Furthermore, in a
carrageenan-induced inflammation model, Amblyostatin-1 decreased edema
formation and neutrophil infiltration into the skin without affecting other
myeloid cells.
Discussion: These findings establish Amblyostatin-1 as a novel salivary cystatin
with immunomodulatory and anti-inflammatory properties, highlighting its
potential as an immunobiological agent. | cs_CZ |
| dc.description.sponsorship | This work was supported by funds from the Sao Paulo Research Foundation (FAPESP; Grants
# 2019/03779-5, 2020/16462-7, 2022/02742-3, and 2024/22525-2),
National Council for Scientific and Technological Development
(CNPq; Grants # 465678/2014-9, 309551/2021-8 and 312674/20210),
and European Regional Development Fund (ERDF; Grants #
CZ.02.1.01/0.0/0.0/15_003/0000441 and CZ.02.01.01/00/23_020/
0008499). LT was supported by the Division of Intramural
Research of the National Institute of Allergy and Infectious
Diseases (Grant # Z01 AI001337-01). WM was a recipient of
fellowships from the Coordination for the Improvement of
Higher Education Personnel (CAPES; Finance code 001) and
FAPESP (Grants # 2022/07724-3 and 2023/07831-7). MK was
supported by Fondation Santé Research Grant in the Biomedical
Sciences. MAJ received the European Union funding (MSCA
fellowship CZ) within the Operational program Jan Amos
Komensky (OP JAK), Priority Research and Development
(Project No. CZ.02.01.01/00/22_010/0003414). | cs_CZ |
| dc.language.iso | en | cs_CZ |
| dc.publisher | FRONTIERS MEDIA SAAVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE CH-1015, SWITZERLAND | cs_CZ |
| dc.relation.ispartofseries | DOI10.3389/fimmu.2025;1585703 | |
| dc.subject | Amblyostatin-1, Amblyomma sculptum, immunomodulation, inflammation, tick-host interaction, tick saliva | cs_CZ |
| dc.title | Amblyostatin-1, the first salivary cystatin with host immunomodulatory and anti-inflammatory properties from the Neotropical tick Amblyomma sculptum, vector of Brazilian spotted fever | cs_CZ |
| dc.type | Article | cs_CZ |